10222 Barnes Canyon Rd. Building #1
22 articles with InVivoScribe Inc.
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System
Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software.
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China
Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network.
Invivoscribe Appoints Loui Madakamutil to Lead Its Therapeutics Division as Chief Scientific Officer
Invivoscribe, Inc., an industry pioneer in developing and commercializing diagnostic products and reagents for hematological malignancies, announced key members of the leadership team hired to direct Invivoscribe Therapeutics, Inc., its fully integrated drug development engine.
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia
Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine.
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
Invivoscribe to offer the LeukoStrat® CDx FLT3 Mutation Assay as an FDA approved kit with analysis software.
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners
Invivoscribe is pleased to announce that their LeukoStrat® CDx FLT3 Mutation Assay was submitted to regulatory authorities in China in April in support of the Astellas New Drug Application submission of XOSPATA® for treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
Invivoscribe Launches COVID-19 Diagnostic Testing With Option To Participate In SARS-CoV-2 Antibody And Vaccine Program
Invivoscribe, Inc., a global leader in the development and commercialization of precision diagnostics announced that they will begin offering coronavirus COVID-19 testing through their CLIA/CAP, NY State Licensed LabPMM reference laboratory in San Diego, CA.
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine.
European Commission Approves Astellas' XOSPATA™ for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay
Invivoscribe, Inc. announced that the European Commission has approved the Astellas drug XOSPATA™ as a monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with FLT3 mutations detected using Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay..
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA
At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay.
InVivoScribe Technologies, Inc. Releases LeukoStrat CDx FLT3 Mutation Assay As CE-marked IVD Assay Kit
InVivoScribe Technologies, Inc. Receives FDA Approval For The Leukostrat Cdx FLT3 Mutation Assay Companion Diagnostic Test For The Selection Of Patients For Rydapt And Is The First Companion Diagnostic For AML
InVivoScribe Technologies, Inc. Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits With Bioinformatics Software And RUO Kits With MRD Software
InVivoScribe Technologies, Inc. Announces Long-Term Collaboration Agreement With Illumina And Plans Release Of NGS-based IVD Assay Kits
InVivoScribe Technologies, Inc. Release: German Supreme Court Upholds And Strengthens Invivoscribe FLT3 Patent Position
InVivoScribe Technologies, Inc. Announces Long-Term Collaboration To Develop Immuno-Oncology Tests With Thermo Fisher Scientific
InVivoScribe Technologies, Inc. Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Test Menu